AIMS: We aimed to perform a systematic review and meta-analysis to assess the association between serum uric acid and incident heart failure (HF)/prognosis of HF patients. METHODS AND RESULTS: A systematic electronic literature search was conducted in Embase (Ovid SP, from 1974 to May 2013), Medline (Ovid SP, from 1946 to May 2013), and the Chinese Biomedical Literature Database (CBM, from 1978 to May 2013) to identify studies reporting on the association between serum uric acid and HF. Either a random effects model or a fixed effects model was used for pooling data. Five studies reporting on incident HF and 28 studies reporting on the adverse outcomes of HF patients were included. The results showed that hyperuricaemia was associated with an increased risk of incident HF [hazard ratio (HR) 1.65, 95% confidence interval (CI) 1.41-1.94], and the risk of all-cause mortality (HR 2.15, 95% CI 1.64-2.83), cardiovascular mortality (HR 1.45, 95% CI 1.18-1.78), and the composite of death or cardiac events (HR 1.39, 95% CI 1.18-1.63) in HF patients. For every 1 mg/dL increase in serum uric acid, the odds of development of HF increased by 19% (HR 1.19, 95% CI 1.17-1.21), and the risk of all-cause mortality and the composite endpoint in HF patients increased by 4% (HR 1.04, 95% CI 1.02-1.06) and 28% (HR 1.28, 95% CI 0.97-1.70), respectively. Subgroup analyses supported the positive association between serum uric acid and HF. CONCLUSIONS: Elevated serum uric acid is associated with an increased risk of incident HF and adverse outcomes in HF patients. First published online by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved.
AIMS: We aimed to perform a systematic review and meta-analysis to assess the association between serum uric acid and incident heart failure (HF)/prognosis of HF patients. METHODS AND RESULTS: A systematic electronic literature search was conducted in Embase (Ovid SP, from 1974 to May 2013), Medline (Ovid SP, from 1946 to May 2013), and the Chinese Biomedical Literature Database (CBM, from 1978 to May 2013) to identify studies reporting on the association between serum uric acid and HF. Either a random effects model or a fixed effects model was used for pooling data. Five studies reporting on incident HF and 28 studies reporting on the adverse outcomes of HF patients were included. The results showed that hyperuricaemia was associated with an increased risk of incident HF [hazard ratio (HR) 1.65, 95% confidence interval (CI) 1.41-1.94], and the risk of all-cause mortality (HR 2.15, 95% CI 1.64-2.83), cardiovascular mortality (HR 1.45, 95% CI 1.18-1.78), and the composite of death or cardiac events (HR 1.39, 95% CI 1.18-1.63) in HF patients. For every 1 mg/dL increase in serum uric acid, the odds of development of HF increased by 19% (HR 1.19, 95% CI 1.17-1.21), and the risk of all-cause mortality and the composite endpoint in HF patients increased by 4% (HR 1.04, 95% CI 1.02-1.06) and 28% (HR 1.28, 95% CI 0.97-1.70), respectively. Subgroup analyses supported the positive association between serum uric acid and HF. CONCLUSIONS: Elevated serum uric acid is associated with an increased risk of incident HF and adverse outcomes in HF patients. First published online by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved.
Authors: U Kiltz; R Alten; M Fleck; K Krüger; B Manger; U Müller-Ladner; H Nüßlein; M Reuss-Borst; A Schwarting; H Schulze-Koops; A Tausche; J Braun Journal: Z Rheumatol Date: 2016-08 Impact factor: 1.372
Authors: Alessandro Maloberti; C Giannattasio; M Bombelli; G Desideri; A F G Cicero; M L Muiesan; E A Rosei; M Salvetti; A Ungar; G Rivasi; R Pontremoli; F Viazzi; R Facchetti; C Ferri; B Bernardino; F Galletti; L D'Elia; P Palatini; E Casiglia; V Tikhonoff; C M Barbagallo; P Verdecchia; S Masi; F Mallamaci; M Cirillo; M Rattazzi; P Pauletto; P Cirillo; L Gesualdo; A Mazza; M Volpe; G Tocci; G Iaccarino; P Nazzaro; L Lippa; G Parati; R Dell'Oro; F Quarti-Trevano; G Grassi; A Virdis; C Borghi Journal: High Blood Press Cardiovasc Prev Date: 2020-03-10
Authors: David Pham; Natalia De Albuquerque Rocha; Darren K McGuire; Ian J Neeland Journal: Trends Cardiovasc Med Date: 2016-08-04 Impact factor: 6.677